All News

Two issues that have a significant impact on pharmaceutical sales divisions will be discussed at the 1999 annual meeting of the National Society of Pharmaceutical Sales Trainers: teamwork and technology.

In a time when mergers and acquisitions are the talk of the pharmaceutical industry, Takeda is generating a different kind of market buzz.

Quality of life for long-term breast cancer survivors is not affected by ethnicity, according to a recent study that appeared in the journal Cancer.

One of the hardest silos to break down in any cross-functional sales effort is the pernicious and often impenetrable wall that has grown up between the sales and marketing functions.

E. Fougera & Co. will celebrate its sesquicentennial this year, the Long Island, NY-based generic pharmaceuticals company announced.

Record spending in research and development by pharmaceutical companies contributed to the FDA approval of 30 new drugs and nine new biologics in 1998, according to a report from Washington-based Pharmaceutical Research and Manufacturers of America.

Novartis releases report

Novartis released its 1998 Pharmacy Benefit Report, a compilation of 1997 pharmacy benefit facts and figures gathered by independent researchers and analysts.

Is the FDA good enough?

Does the United States need an independent drug safety board to investigate FDA-approved medicines?

The pharmaceutical industry sharply criticized new legislation that proposes offering Medicare beneficiaries deep pricing discounts on prescription medicines.

Hospital-based registered nurses report that fewer patients are being harmed by medical errors than was the case 10 years ago.

The annual rate of change for prescription pharmaceutical prices in the United States held at 3.4% in the third quarter of 1998, compared to the third quarter of 1997.